Source comparison
Dosing Principles: Signaling Threshold vs Receptor Saturation
BPC-157 doesn't work through traditional receptor binding kinetics. It modulates VEGF (vascular endothelial growth factor) expression, upregulates growth hormone receptors in damaged tissue, and enhances fibroblast migration to injury sites. The therapeutic wi
This comparison does not assign a generated winner or score.
- BPC-157 doesn't work through traditional receptor binding kinetics. It modulates VEGF (vascular endothelial growth factor) expression, upregulates growth hormone receptors in damaged tissue, and enhances fibroblast migration to injury sites. The therapeutic window exists because these pathways respond to concentration gradients, not absolute peptide quantity. Animal studies demonstrate dose-dependent effects up to approximately 10mcg/kg, after which healing rates plateau. Human extrapolations. Accounting for metabolic rate differences and body surface area scaling. Place the effective range at 200–500mcg daily for a 70kg individual, with 250–350mcg showing the most consistent tissue repair outcomes in clinical observations.
- The injection site matters more than total dose. Subcutaneous administration within 2–5cm of the injury creates a local concentration gradient that drives angiogenesis and collagen deposition at the repair site. Systemic administration (intramuscular injection distant from injury, or oral delivery) dilutes the peptide across the entire circulatory system, reducing local tissue concentrations below the signaling threshold. A 2018 study published in the Journal of Physiology and Pharmacology found that locally administered BPC-157 accelerated Achilles tendon healing in rats by 56% at 14 days, while systemic administration at the same total dose showed no significant difference from controls.
- Dosing frequency affects stability. BPC-157 has an estimated half-life of 4–6 hours in vivo, meaning twice-daily dosing maintains more consistent tissue levels than once-daily bolus administration. Researchers using 250mcg twice daily (500mcg total) report faster initial healing compared to 500mcg once daily, likely because the peptide concentration remains above the signaling threshold for a longer proportion of the 24-hour cycle.